A 2014 review assessed MAT with methadone or buprenorphine-containing agents.
Interventions of Interest:
- Buprenorphine (Subutex®, Reckitt Benckiser Pharmaceuticals Inc.
- Buprenorphine and naloxone (Suboxone®, Indivior Inc.)
- Dose-tapering strategies for methadone or Suboxone, with or without naltrexone (Revia®, Duramed Pharmaceuticals, Inc.
- Naltrexone (Vivitrol®, Alkermes, Inc.)
- Use of naltrexone alone without prior stabilization on methadone or buprenorphine
- Drug-free opioid withdrawal management
For questions or additional information, please contact firstname.lastname@example.org
Below you will find the final documents from the assessment review process: